Assembly Biosciences Announces ABI-H0731 Phase 1b Interim Data Accepted as a Late-Breaker Poster at The International Liver Congress™ (EASL)

INDIANAPOLIS and SAN FRANCISCO, March 28, 2018 (GLOBE NEWSWIRE) — Assembly Biosciences, Inc. (NASDAQ: ASMB ), a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel oral live biotherapeutics for disorders….


Read all

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.